微信公众号

官网二维码

中国癌症防治杂志 ›› 2026, Vol. 18 ›› Issue (1): 98-105.doi: 10.3969/j.issn.1674-5671.2026.01.12

• 论著 • 上一篇    下一篇

CMTM6通过负向调控CXCL8参与肝癌上皮-间质转化及恶性进展

  

  1. 桂林医科大学广西环境暴露组学与全生命周期健康重点实验室;右江民族医学院附属医院广西肝胆疾病临床医学研究中心;广西医科大学附属柳州市人民医院急诊医学科
  • 出版日期:2026-02-25 发布日期:2026-03-27
  • 通讯作者: 朱小年 E-mail: zhuxiaonian0403@163.com; 谭盛葵 E-mail: sktan2008@163.com
  • 基金资助:
    国家自然科学基金项目(82560669);广西重点研发计划项目(桂AB25069071)

CMTM6 regulates epithelial-mesenchymal transition and malignant progression of  liver cancer by repressing CXCL8

  • Online:2026-02-25 Published:2026-03-27

摘要: 目的 探讨CXC趋化因子配体8(C⁃X⁃C motif chemokine ligand 8, CXCL8)对肝癌细胞恶性生物学行为的调控作用及其潜在的分子机制,为肝癌靶向治疗提供潜在靶点和理论依据。 方法 采用qPCR检测CXCL8在肝癌细胞HepG2、MHCC97H、Hep3B和Huh7中的表达情况,筛选出表达水平中等的Hep3B细胞进行研究。采用慢病毒感染及质粒转染技术,构建CXCL8敲低与过表达、CKLF样MARVEL跨膜结构域包含蛋白6(CKLF⁃like MARVEL transmembrane domain⁃containing ptotein 6, CMTM6)敲低与过表达以及CMTM6敲低联合CXCL8过表达的Hep3B细胞模型。采用qPCR检测细胞中CXCL8、CMTM6及上皮⁃间质转化(epithelial⁃mesenchymal transition,EMT)标志分子(E⁃cadherin、β⁃catenin、N⁃cadherin、Vimentin)的mRNA表达水平,通过CCK⁃8法、划痕实验及Transwell实验检测细胞的增殖、迁移与侵袭能力。 结果 敲低CXCL8可显著抑制Hep3B细胞的增殖、迁移和侵袭(均P<0.01),上调E⁃cadherin、β⁃catenin表达(均P<0.05),下调N⁃cadherin、Vimentin表达(均P<0.01);过表达CXCL8则呈现相反效应(均P<0.05)。CMTM6过表达可显著降低CXCL8 mRNA的表达(P<0.001),而CMTM6敲低则显著上调CXCL8 mRNA的表达(P<0.001)。敲低CMTM6可显著抑制Hep3B细胞增殖、迁移和侵袭(均P<0.001),上调E⁃cadherin、β⁃catenin表达(均P<0.05),下调N⁃cadherin、Vimentin表达(均P<0.05);而同时过表达CXCL8则可部分逆转上述效应(均P<0.05)。 结论 CXCL8通过诱导EMT促进肝癌细胞增殖、迁移和侵袭,其机制可能与CMTM6在转录水平上负向调控CXCL8的表达有关,提示靶向CMTM6与CXCL8的调控网络可能成为肝癌治疗的新策略。

关键词: 肝癌, CXC趋化因子配体8(CXCL8), 上皮?间质转化, CKLF样MARVEL跨膜结构域包含蛋白6(CMTM6)

Abstract: Objective To investigate the regulatory effect of C⁃X⁃C motif chemokine ligand 8 (CXCL8) on the malignant biological behaviors of liver cancer cells, and to elucidate the underlying molecular mechanisms mediated by CKLF⁃like MARVEL transmembrane domain⁃containing protein 6 (CMTM6). The findings are expected to provide potential therapeutic targets and a theoretical foundation for the development of targeted therapy in liver cancer. Methods The expression levels of CXCL8 in the liver cancer cell lines HepG2, MHCC97H, Hep3B, and Huh7 were detected by real⁃time quantitative polymerase chain reaction (qPCR), and Hep3B cells which exhibited moderate expression levels, were selected for subsequent investigation. To establish Hep3B cell models, lentiviral and plasmid transfection were used to generate CXCL8 knockdown (CXCL8KD), CXCL8 overexpression (CXCL8OE), CMTM6 knockdown (CMTM6KD), and CMTM6KD combined with CXCL8OE cell lines. qPCR was performed to measure mRNA expression levels of CXCL8, CMTM6, and markers of epithelial⁃mesenchymal transition (EMT) , including E⁃cadherin, β⁃catenin, N⁃cadherin, and Vimentin. CCK⁃8, wound healing, and Transwell assays were used to detected the cell proliferation, migration, and invasion, respectively. Results CXCL8 knockdown significantly inhibited the proliferation, migration, and invasion of Hep3B cells (all P<0.01), which was associated with an upregulation of E⁃cadherin and β⁃catenin expression (all P<0.05), and a downregulation of N⁃cadherin and Vimentin expression (all P<0.01), whereas CXCL8 overexpression showed opposite effects (all P<0.05). CMTM6 overexpression significantly downregulated CXCL8 mRNA expression (P<0.001), while CMTM6 knockdown significantly upregulated CXCL8 mRNA expression (P<0.001). CMTM6 knockdown significantly inhibited Hep3B cell proliferation, migration, and invasion (all P<0.001), upregulated E⁃cadherin and β⁃catenin (all P<0.05), and downregulated N⁃cadherin and Vimentin (all P<0.05). Notably, simultaneous CXCL8 overexpression partially reversed these effects (all P<0.05). Conclusions CXCL8 has been identified as a downstream target gene of CMTM6 in liver cancer. CXCL8 may promote the proliferation, migration, and invasion of liver cancer cells by inducing EMT, and this mechanism may be associated with the negative regulation of CXCL8 expression by CMTM6 at the transcriptional level.This suggests that targeting the regulatory network involving CMTM6 and CXCL8 may offer a novel therapeutic strategy for the treatment of liver cancer.

Key words: Liver cancer, C?X?C motif chemokine ligand 8 (CXCL8), Epithelial?mesenchymal transition, CKLF?like MARVEL transmembrane domain?containing ptotein 6 (CMTM6)

中图分类号: 

  • R735.7